CryoPatch^® SG Reduces PRA In Right Ventricular Outflow Tract Patients

Implantation of the CryoPatch SG Pulmonary Human Cardiac Patch reduces the risk for induction of HLA class I and class II alloantibodies based on Panel Reactive Antibody (PRA) measured at up to one year, compared to the standard-processed pulmonary human cardiac tissue. Data have not been provided to evaluate the effect of reduced HLA class I and class II alloantibodies on the longterm durability, or long-term resistance to rejection by the patient, of the CryoPatch SG.

When faced with the complexities of cardiac reconstructions for defects such as Tetralogy of Fallot, Truncus Arteriosis, Pulmonary Atresia, and more, CryoLife offers the flexibility of the CryoPatch SG pulmonary hemi-artery.

Applications
The pulmonary hemi-artery is transected in a vertical fashion midpoint of pulmonary artery bifurcation.

• Availability: < 30mm proximal base and < 1.0cm branch length.
• Applications include
  • Congenital reconstructions
  • RVOT

When an allograft patch material is needed for cardiac reconstruction, CryoPatch SG pulmonary artery trunk patch offers a thicker alternative to pulmonary branch patch, while offering the same natural characteristics as the patient's own tissue.

Applications
The pulmonary artery is transected at the top of the commissural posts and across the conduit at the bifurcation.

• Availability: 2.5cm length x 3.0cm width or greater size sheet.
• Applications include
  • Congenital reconstructions
  • RVOT

The naturally attractive characteristics of pulmonary branch material cryopreserved by CryoLife makes the CryoPatch SG pulmonary artery branch patch the natural alternative when patch material is needed.

Applications
The pulmonary artery branch is transected from the conduit and opened up into a flat sheet.

• Availability: 2.5cm length x 3.0cm width or greater size sheet.
• Applications include
  • Congenital reconstructions
  • RVOT